Gain Therapeutics/$GANX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gain Therapeutics
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
- Ticker
- $GANX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Bethesda, United States
- Website
- gaintherapeutics.com
GANX Metrics
BasicAdvanced
$48M
-
-$0.43
-
-
Price and volume
Market cap
$48M
52-week high
$4.34
52-week low
$0.94
Average daily volume
535K
Financial strength
Current ratio
5.36
Quick ratio
4.972
Long term debt to equity
0.04
Total debt to equity
0.067
Profitability
EBITDA (TTM)
-17.678
Effective tax rate (TTM)
-2.45%
Management effectiveness
Return on assets (TTM)
-91.54%
Return on equity (TTM)
-223.94%
Valuation
Price to book
4.85
Price to tangible book (TTM)
4.88
Price to free cash flow (TTM)
-2.71
Free cash flow yield (TTM)
-36.90%
Free cash flow per share (TTM)
-0.41
Growth
Earnings per share change (TTM)
-32.46%
3-year earnings per share growth (CAGR)
-38.08%
What the Analysts think about GANX
Analyst ratings (Buy, Hold, Sell) for Gain Therapeutics stock.
Analyst projections of the future price of Gain Therapeutics stock.
GANX Financial Performance
Revenues and expenses
GANX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.